Will Botanix Pharmaceuticals Ltd burn out?

Botanix Pharmaceuticals Ltd (ASX: BOT) is in the midst of a research and development programme that seeks to further understand and utilise cannabidiol, an ingredient found in cannabis, to treat skin conditions.

Scientific research by Botanix and others has found that cannabidiol “plays a significant role” in combatting skin conditions by normalising skin growth, reducing inflammation, infection, and decreasing the production of excessive oils.

Botanix has contributed to such studies and played a part in the further understanding of the medical benefits of cannabidiol having recently announced that clinical studies of its BTX 1503 product produced positive results.

The pharmaceutical company stated that its study of BTX 1503 has shown that it can combat white heads, black heads and other skin complications.

But the research and development has come at a cost.

The question is: Is Botanix spending too much?

For the quarter ended 31 December 2017 Botanix announced that it had spent about $2 million, with the bulk of that going towards research and development, and it finished the period with cash and cash equivalents of about $2.2 million.

At its current burn rate, based on its latest cash flow report, the end of Botanix’s financial runway is fast approaching.

What’s more, when stacked up against other medical marijuana companies Auscann Group Holdings Ltd (ASX: AC8) and the Hydroponics Company Ltd (ASX: THC), Botanix’s financial standing appears worse.

Botanix is burning cash at a much faster rate and has significantly less cash behind it than both those companies.

As such Bontanix has gone into a trading halt as it prepares to make an announcement regarding capital raising.

Research and development is obviously an expensive process but the rate at which Botanix is burning through its funds would raise questions for many.

It also illustrates that the management of other medical marijuana companies appears to be taking more disciplined approaches than that of Botanix’s management.

Botanix shares are expected to resume trading on Monday.

Don’t Buy A SINGLE Stock Until You Read This

While conflict overseas is all media talking-heads seem to mention these days, the billionaire founder of Tesla is losing sleep over what he sees as a far bigger threat.

Elon Musk Warns: This has “vastly more risk than North Korea”

If you missed your opportunity to get in on Google, Microsoft, or Amazon in their early days, don't let it happen again. This emerging technology trend could offer a second chance for anyone who wishes they took part in these millionaire-maker stocks.

Click here to discover more!

Motley Fool contributor Steve Holland has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.